Literature DB >> 32369256

Comparative Study of Amide Proton Transfer-Weighted Imaging and Intravoxel Incoherent Motion Imaging in Breast Cancer Diagnosis and Evaluation.

Nan Meng1,2, Xue-Jia Wang3, Jing Sun4, Ling Huang5, Zhe Wang6, Kai-Yu Wang7, Jing Wang3, Dong-Ming Han3, Mei-Yun Wang1,2.   

Abstract

BACKGROUND: Amide proton transfer-weighted imaging (APTWI) and intravoxel incoherent motion imaging (IVIM) are valuable MRI techniques applied to cancer.
PURPOSE: To compare APTWI and IVIM in the diagnosis of benign and malignant breast lesions and to evaluate the correlations between different parameters (MTRasym [3.5 ppm], D, D*, and f) and prognostic factors for breast cancer. STUDY TYPE: Retrospective. POPULATION: In all, 123 breast lesions were studied before treatment, including 58 benign lesions and 65 malignant lesions. FIELD STRENGTH/SEQUENCE: Conventional MRI (T1 WI, T2 WI, and diffusion-weighted imaging [DWI]), APTWI, and IVIM MRI at 3T. ASSESSMENT: The magnetization transfer ratio asymmetry at 3.5 ppm (MTRasym [3.5 ppm]), diffusion coefficient (D), pseudo diffusion coefficient (D*), and perfusion fraction (f) values were compared between the benign and malignant groups and between groups with different expression levels of prognostic factors. STATISTICAL TESTS: Individual sample t-test, χ2 test, Spearman correlation, logistic regression, and the Delong test.
RESULTS: The D and MTRasym (3.5 ppm) values of the malignant group were lower than those of the benign group; however, D* and f values were higher than those of the benign group (all P < 0.05). The areas under the curve (AUCs) of D, MTRasym (3.5 ppm), D*, and f were 0.809, 0.778, 0.670, and 0.766, respectively; however, only the difference between AUC (D) and AUC (D*) was significant (Z = 2.374, P < 0.05). The D value showed a low correlation with the pathological grade and Ki-67 expression (| r | = 0.294, 0.367); the f value showed a low correlation with estrogen receptor (ER) expression (| r | = 0.382); and the MTRasym (3.5 ppm) value showed a low correlation with pathological grade (| r | = 0.371). DATA
CONCLUSION: This analysis revealed that both IVIM and APTWI could be used for the differential diagnosis of benign and malignant breast lesions, and APTWI-derived MTRasym (3.5 ppm), IVIM-derived D, D*, and f values showed correlations with some prognostic factors for breast cancer. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY STAGE: 2 J. Magn. Reson. Imaging 2020;52:1175-1186.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  amide proton transfer-weighted imaging; breast cancer; intravoxel incoherent motion imaging

Mesh:

Substances:

Year:  2020        PMID: 32369256     DOI: 10.1002/jmri.27190

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

Review 1.  A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging.

Authors:  Tianxin Gao; Chuyue Zou; Yifan Li; Zhenqi Jiang; Xiaoying Tang; Xiaolei Song
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

2.  Prediction of Prognostic Factors and Genotypes in Patients With Breast Cancer Using Multiple Mathematical Models of MR Diffusion Imaging.

Authors:  Weiwei Wang; Xindong Zhang; Laimin Zhu; Yueqin Chen; Weiqiang Dou; Fan Zhao; Zhe Zhou; Zhanguo Sun
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

3.  Simplified intravoxel incoherent motion DWI for differentiating malignant from benign breast lesions.

Authors:  Petra Mürtz; Mark Tsesarskiy; Alois M Sprinkart; Wolfgang Block; Oleksandr Savchenko; Julian A Luetkens; Ulrike Attenberger; Claus C Pieper
Journal:  Eur Radiol Exp       Date:  2022-09-29

4.  Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Quantitative Differentiation of Breast Tumors: A Meta-Analysis.

Authors:  Jianye Liang; Sihui Zeng; Zhipeng Li; Yanan Kong; Tiebao Meng; Chunyan Zhou; Jieting Chen; YaoPan Wu; Ni He
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.